Melissa Etheridge to be Honored at 20th Annual HOPE Luncheon for Mental Health Advocacy

Celebrating Mental Health Advocacy

On November 10, 2026, the Hope for Depression Research Foundation (HDRF) will host its 20th Annual HOPE Luncheon Seminar at The Plaza Hotel in New York City, honoring the renowned Grammy and Academy Award-winning artist, Melissa Etheridge. This year's theme, "20 Years of Research Emerging New Treatments," focuses on significant breakthroughs in depression research, addressing the urgent need for better treatment options.

The event, which also marks HDRF's 20th anniversary, will feature a lineup of esteemed guests, including Chuck Scarborough, the acclaimed television journalist and author, who will serve as the Master of Ceremonies. Attendees will be treated to invaluable insights from leading medical experts discussing innovative treatments for depression stemming from HDRF’s unique research initiatives.

Keynote speaker, Dr. Husseini Manji, has made a name for himself as a major contributor to depression treatment innovations. Having been instrumental in the development of Spravato, a nasal spray designed to combat depression and suicidal thoughts, he brings a wealth of knowledge to the discussion on emerging therapies. Currently, he serves as the Co-Chair of the UK Government Mental Health Mission, continuing his commitment to mental health advocacy.

Etheridge, known not only for her musical talent but also for her substantial advocacy efforts, will receive the prestigious 2026 Hope Award for her advocacy in mental health. She founded The Etheridge Foundation with a mission to support pioneering research into new plant-based medicines and psychedelic treatments aimed at addressing opioid use disorder. Her dedication to improving mental health awareness and solutions has inspired many in the fight against depression.

Audrey Gruss, the founder and chair of HDRF, remarked on the significance of the event, stating, “Twenty years ago, I founded HDRF to bring velocity to the stalled field of depression research. We urgently need new treatments to move away from the standard SSRI medications, which often fall short for many patients.” Gruss emphasized that HDRF is progressing through pilot clinical trials that aim to pave the way for precision treatment tailored for individual patient needs.

Additionally, the program will highlight pivotal discoveries made by HDRF's esteemed Depression Task Force, an international group of leading neuroscientists formed in 2012 to expedite research in depression. This Task Force is at the forefront of depression research in the United States, driving innovative approaches to treatment.

Definium Therapeutics will be recognized with the 2026 Corporate Visionary Award for its contributions to exploring psychedelic treatments through advancements in neuroscience and clinical research. Furthermore, the HDRF Clinical Trial/Drug Discovery Program Founders Group will be awarded the 2026 Hope Community Award for initiating the foundation's first pilot clinical trials. The honorees include prominent figures such as Deborah and Steven Barnes, Brent R. Nicklas Foundation/Richard Roeder, D3, Jamee and Peter Gregory, along with Pauline Pitt and Barbara and Randall Smith.

The HOPE Luncheon not only honors those making strides in mental health but also serves as a vital platform to fund future groundbreaking research. By raising both awareness and essential funds, this event seeks to break down the barriers surrounding depression and enhance the lives of countless individuals affected by this pervasive mental health challenge. For further details, visit Hope for Depression’s website.

In conclusion, the 20th Annual HOPE Luncheon promises to be a memorable occasion, celebrating not only the achievements in mental health research but the inspiring efforts of advocates like Melissa Etheridge. It is a reminder of why ongoing support and innovative approaches are crucial in the fight for better mental health solutions.